Search research articles
Contact Us
Filters
Showing results (1-10 of 19) with videos related to
Page
of 2
Sort By:
Anti-Cancer Drugs
|
September 22, 2011
Systemic chemotherapy in patients with advanced transitional cell carcinoma of the urothelium and impaired renal function
Mounira El Demery, Simon Thézenas, Damien Pouessel, et al.
Clinical & Experimental Metastasis
|
November 10, 2014
Bone metastases in gastrointestinal cancer
Fabienne Portales, Simon Thézenas, Emmanuelle Samalin, et al.
Frontiers in Immunology
|
December 22, 2022
Correlation of the TIGIT-PVR immune checkpoint axis with clinicopathological features in triple-negative breast cancer
Florence Boissière-Michot, Marie-Christine Chateau, Simon Thézenas, et al.
Oncology Reports
|
September 6, 2005
Inter- and intra-individual variability in transdermal fentanyl absorption in cancer pain patients
Isabelle Solassol, Laetitia Caumette, Françoise Bressolle, et al.
International Journal of Cancer
|
July 28, 2016
Serum NSE, MMP-9 and HER2 extracellular domain are associated with brain metastases in metastatic breast cancer patients: predictive biomarkers for brain metastases?
Amélie Darlix, Pierre-Jean Lamy, Evelyne Lopez-Crapez, et al.
Recherche En Soins Infirmiers
|
June 20, 2022
Catherine Lacroix, Geneviève Georges, Simon Thézenas, et al.
Recherche En Soins Infirmiers
|
June 12, 2020
[The role of the specialist nurse in parenteral nutrition : An observational study of complications with home parenteral nutrition in adult cancer patients]
Catherine Lacroix, Geneviève Georges, Simon Thézenas, et al.
Frontiers in Immunology
|
December 26, 2024
Prognostic value of tertiary lymphoid structures in triple-negative breast cancer: integrated analysis with the tumor microenvironment and clinicopathological features
Florence Boissière-Michot, Marie-Christine Chateau, Simon Thézenas, et al.
Virchows Archiv : an International Journal of Pathology
|
February 4, 2026
Exploring the spectrum of HER2 in non-metastatic triple negative breast cancer: from HER2-Null to HER2-low, including HER2-ultralow status
Florence Boissière-Michot, Amélie Gudin-De-Vallerin, Simon Thézenas, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 27, 2010
Inter-observer agreement between dermatologists and oncologists in assessing dermatological toxicities in patients with metastatic colorectal cancer treated by cetuximab-based chemotherapies: a pilot comparative study
Jacqueline Duffour, Simon Thézenas, Olivier Dereure, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 19) with videos related to
Sort By:
Page
of 2
Anti-Cancer Drugs
|
September 22, 2011
Systemic chemotherapy in patients with advanced transitional cell carcinoma of the urothelium and impaired renal function
Mounira El Demery, Simon Thézenas, Damien Pouessel, et al.
Clinical & Experimental Metastasis
|
November 10, 2014
Bone metastases in gastrointestinal cancer
Fabienne Portales, Simon Thézenas, Emmanuelle Samalin, et al.
Frontiers in Immunology
|
December 22, 2022
Correlation of the TIGIT-PVR immune checkpoint axis with clinicopathological features in triple-negative breast cancer
Florence Boissière-Michot, Marie-Christine Chateau, Simon Thézenas, et al.
Oncology Reports
|
September 6, 2005
Inter- and intra-individual variability in transdermal fentanyl absorption in cancer pain patients
Isabelle Solassol, Laetitia Caumette, Françoise Bressolle, et al.
International Journal of Cancer
|
July 28, 2016
Serum NSE, MMP-9 and HER2 extracellular domain are associated with brain metastases in metastatic breast cancer patients: predictive biomarkers for brain metastases?
Amélie Darlix, Pierre-Jean Lamy, Evelyne Lopez-Crapez, et al.
Recherche En Soins Infirmiers
|
June 20, 2022
Catherine Lacroix, Geneviève Georges, Simon Thézenas, et al.
Recherche En Soins Infirmiers
|
June 12, 2020
[The role of the specialist nurse in parenteral nutrition : An observational study of complications with home parenteral nutrition in adult cancer patients]
Catherine Lacroix, Geneviève Georges, Simon Thézenas, et al.
Frontiers in Immunology
|
December 26, 2024
Prognostic value of tertiary lymphoid structures in triple-negative breast cancer: integrated analysis with the tumor microenvironment and clinicopathological features
Florence Boissière-Michot, Marie-Christine Chateau, Simon Thézenas, et al.
Virchows Archiv : an International Journal of Pathology
|
February 4, 2026
Exploring the spectrum of HER2 in non-metastatic triple negative breast cancer: from HER2-Null to HER2-low, including HER2-ultralow status
Florence Boissière-Michot, Amélie Gudin-De-Vallerin, Simon Thézenas, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 27, 2010
Inter-observer agreement between dermatologists and oncologists in assessing dermatological toxicities in patients with metastatic colorectal cancer treated by cetuximab-based chemotherapies: a pilot comparative study
Jacqueline Duffour, Simon Thézenas, Olivier Dereure, et al.
Page
of 2